Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Fulgent Genetics Reports Second Quarter 2022 Financial Results
August 4, 2022 4:05 PM EDTRevenue totals $125.3 million Core Revenue grows 102% year-over-year to $45.3 million Raises full year core revenue outlook to $185 million from previously announced $180 million
TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics, Fulgent, or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022.
Second Quarter 2022 Results:
Revenue of $125.3 million, versus $153.6 million in Q2 2021 Billable tests... More